You searched for "surgical"
Bladder cancer: where are we with intravesical therapies?
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...Use of MRI in the evaluation of prostate cancer: part 1
Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...Sustainable healthcare: what steps can urologists take?
Human health is intrinsically linked to environmental health, making the ever-pressing climate crisis fundamentally a public health emergency. The healthcare sector is responsible for 8% of the UK’s greenhouse gas (GHG) emissions worldwide [1]. As the largest publicly funded healthcare...Action Bladder Cancer UK launches learning module for primary care
Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...
Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer
Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...Radiological appearances of renal vascular anatomical variants
The purpose of this article is to explain and illustrate common renal vascular variants that can be depicted with imaging. Renal vessels commonly present a wide range of variations [1]; before major renal or vascular surgery is undertaken, accurate portrayal...Prostate Cancer Issue II
UK urology has truly been at the forefront of clinical research to change the prostate cancer pathway for the better. We should be rightly proud of what we have achieved over the last 10 years together in the clinical and...
Comparing intravesical chemohyperthermia with Mitomycin C versus BCG in treating bladder cancer
In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...
HPV prevalence in invasive penile cancer and association with clinical outcome
Penile cancer risks can be increased by a number of causes such as smoking, phimosis, poor hygiene, multiple sexual partners and history of gential warts or other sexually transmitted diseases. It has been found that circumcised men have a lower...
The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease
End stage renal disease (ESRD) patients in need of a kidney transplant who have a previous history of urological cancer should undergo a cancer-free waiting period before receiving a kidney transplant. Currently the recommended waiting time is based on the...
Can PET/CT help in selecting treatment for patients with muscle-invasive bladder cancer more appropriately?
Radical cystectomy is one of the most drastic procedures that urological patients have to undergo with a five-year mortality of around 50% in those with organ-confined disease at presentation. Traditional imaging is with contrast-enhanced computed tomography (CT) but lymphadenectomy often...
